Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
10
5
2021
medline:
30
12
2021
entrez:
9
5
2021
Statut:
ppublish
Résumé
Cutaneous melanoma is the most lethal type of skin cancer. Early detection is crucial to improve the outcome of melanoma patients. The identification of noninvasive prognostic biomarkers for the follow-up of melanoma patients is still in demand for clinical use. We show here that exosomal melanotransferrin fulfills the biomarker characteristics required to meet this demand. Melanotransferrin is typically overexpressed in melanoma cells compared to other cell types - including cancer cells - and is efficiently sorted and secreted with nanovesicles, or so-called exosomes, due to its membrane-anchoring by a glycosylphosphatidylinositol. Melanotransferrin is exposed on the surface of exosomes and is accessible for antibody recognition. An ELISA was set up to quantify melanotransferrin after immobilization of nanovesicles through the exosomal constituent tetraspanins CD63. Melanotransferrin was detected using a low number of exosomes purified from melanoma cell line cultures, and melanotransferrin detection was abolished by phosphatidylinositol-specific phospholipase C treatment. This exosomal melanotransferrin ELISA was able to discriminate an equal number of assayed exosomes purified from two different melanoma cell lines (A-375 vs. SK-MEL-28). Moreover, plasma samples from patients with melanoma and noncancer disease were assayed using this ELISA and elevated levels of exosomal melanotransferrin were seen in the plasma of patients with melanoma. We propose that exosomal melanotransferrin should be assessed as a potential melanoma biomarker.
Identifiants
pubmed: 33965973
doi: 10.1097/CMR.0000000000000741
pii: 00008390-202108000-00007
doi:
Substances chimiques
MELTF protein, human
0
Membrane Glycoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
338-351Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Vennepureddy A, Thumallapally N, Motilal Nehru V, Atallah JP, Terjanian T. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res. 2016; 8:63–75
Achkar T, Tarhini AA. The use of immunotherapy in the treatment of melanoma. J Hematol Oncol. 2017; 10:88
Stahlecker J, Gauger A, Bosserhoff A, Büttner R, Ring J, Hein R. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 2000; 20:5041–5044
Krähn G, Kaskel P, Sander S, Waizenhöfer PJ, Wortmann S, Leiter U, Peter RU. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001; 21:1311–1316
Henry L, Fabre C, Guiraud I, Bastide S, Fabbro-Peray P, Martinez J, et al. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. Int J Cancer. 2013; 133:142–148
Lim SY, Lee JH, Diefenbach RJ, Kefford RF, Rizos H. Liquid biomarkers in melanoma: detection and discovery. Mol Cancer. 2018; 17:8
Tarhini A, Kudchadkar RR. Predictive and on-treatment monitoring biomarkers in advanced melanoma: moving toward personalized medicine. Cancer Treat Rev. 2018; 71:8–18
Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016; 113:E968–E977
Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro : selective externalization of the receptor. Cell. 1983; 33:967–978
Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. 1983; 97:329–339
Van Laar R, Lincoln M, Van Laar B. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. Br J Cancer. 2018; 118:857–866
Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, et al. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. Proc Natl Acad Sci U S A. 2017; 114:E5930–E5939
Vidal M. Exosomes and GPI-anchored proteins: judicious pairs for investigating biomarkers from body fluids. Adv Drug Deliv Rev. 2020; 161–162:110–123
Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987; 262:9412–9420
Rabesandratana H, Toutant JP, Reggio H, Vidal M. Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during In vitro maturation of reticulocytes. Blood. 1998; 91:2573–2580
Brown JP, Nishiyama K, Hellström I, Hellström KE. Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. J Immunol. 1981; 127:539–546
Alemany R, Vilá MR, Francí C, Egea G, Real FX, Thomson TM. Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): apical compartmentalization in intestinal epithelial cells. J Cell Sci. 1993; 104Pt 41155–1162
Dippold WG, Lloyd KO, Li LT, Ikeda H, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1980; 77:6114–6118
Bec N, Bonhoure A, Henry L, Berry L, Larroque C, Coux O, et al. Proteasome 19S RP and translation preinitiation complexes are secreted within exosomes upon serum starvation. Traffic. 2019; 20:516–536
Bonhoure A, Vallentin A, Martin M, Senff-Ribeiro A, Amson R, Telerman A, Vidal M. Acetylation of translationally controlled tumor protein promotes its degradation through chaperone-mediated autophagy. Eur J Cell Biol. 2017; 96:83–98
Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem. 1981; 256:1604–1607
Kim HY, Lee H, Kim SH, Jin H, Bae J, Choi HK. Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling. Sci Rep. 2017; 7:8864
Lazar I, Clement E, Ducoux-Petit M, Denat L, Soldan V, Dauvillier S, et al. Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines. Pigment Cell Melanoma Res. 2015; 28:464–475
Rossi S, Cordella M, Tabolacci C, Nassa G, D’Arcangelo D, Senatore C, et al. TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness. J Exp Clin Cancer Res. 2018; 37:326
Suryo Rahmanto Y, Dunn LL, Richardson DR. The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark–from iron metabolism to tumorigenesis. Oncogene. 2007; 26:6113–6124
Hamamura K, Tsuji M, Hotta H, Ohkawa Y, Takahashi M, Shibuya H, et al. Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J Biol Chem. 2011; 286:18526–18537
Hamamura K, Furukawa K, Hayashi T, Hattori T, Nakano J, Nakashima H, et al. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acad Sci U S A. 2005; 102:11041–11046
Yang J, Tiong J, Kennard M, Jefferies WA. Deletion of the GPI pre-anchor sequence in human p97–a general approach for generating the soluble form of GPI-linked proteins. Protein Expr Purif. 2004; 34:28–48
Brown JP, Woodbury RG, Hart CE, Hellström I, Hellström KE. Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A. 1981; 78:539–543
Food MR, Rothenberger S, Gabathuler R, Haidl ID, Reid G, Jefferies WA. Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein. J Biol Chem. 1994; 269:3034–3040
de Gassart A, Geminard C, Fevrier B, Raposo G, Vidal M. Lipid raft-associated protein sorting in exosomes. Blood. 2003; 102:4336–4344
Dermine JF, Duclos S, Garin J, St-Louis F, Rea S, Parton RG, Desjardins M. Flotillin-1-enriched lipid raft domains accumulate on maturing phagosomes. J Biol Chem. 2001; 276:18507–18512
Stieger S, Brodbeck U. Glycosyl-phosphatidylinositol anchored acetylcholinesterase as substrate for phosphatidylinositol-specific phospholipase C from Bacillus cereus. Biochimie. 1991; 73:1179–1186
Woodbury RG, Brown JP, Yeh MY, Hellström I, Hellström KE. Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A. 1980; 77:2183–2187
Wang Z, Luo C, Wang H, Yan X, Liu W, Meng Z. CEACAM6 is associated with osteosarcoma metastasis and facilitates epithelial-mesenchymal transition in osteosarcoma cells. Onco Targets Ther. 2018; 11:3159–3166
Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer. 2007; 7:2
Gebauer F, Wicklein D, Horst J, Sundermann P, Maar H, Streichert T, et al. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. PLoS One. 2014; 9:e113023
Schölzel S, Zimmermann W, Schwarzkopf G, Grunert F, Rogaczewski B, Thompson J. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol. 2000; 156:595–605
Lewis-Wambi JS, Cunliffe HE, Kim HR, Willis AL, Jordan VC. Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer. 2008; 44:1770–1779
Henry L, Le Gallic L, Garcin G, Coux O, Jumez N, Roger P, et al. Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin. Br J Dermatol. 2011; 165:311–320
Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 2014; 5:3591
Im H, Shao H, Park YI, Peterson VM, Castro CM, Weissleder R, Lee H. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol. 2014; 32:490–495
Stahl PD, Raposo G. Extracellular vesicles: exosomes and microvesicles, integrators of homeostasis. Physiology (Bethesda). 2019; 34:169–177
Vidal M. Exosomes: revisiting their role as “garbage bags”. Traffic. 2019; 20:815–828
Kakurina GV, Cheremisina OV, Choinzonov EL, Kondakova IV. Circulating proteasomes in the pathogenesis of head and neck squamous cell carcinoma. Bull Exp Biol Med. 2017; 163:92–94
Manasanch EE, de Larrea CF, Zingone A, Steinberg SM, Kwok M, Tageja N, et al. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leuk Lymphoma. 2017; 58:639–645
de Martino M, Hoetzenecker K, Ankersmit HJ, Roth GA, Haitel A, Waldert M, Klatte T. Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis. Br J Cancer. 2012; 106:904–908
Pfeffer SR, Grossmann KF, Cassidy PB, Yang CH, Fan M, Kopelovich L, et al. Detection of exosomal miRNAs in the plasma of melanoma patients. J Clin Med. 2015; 4:2012–2027
Cvjetkovic A, Jang SC, Konečná B, Höög JL, Sihlbom C, Lässer C, Lötvall J. Detailed Analysis of protein topology of extracellular vesicles-evidence of unconventional membrane protein orientation. Sci Rep. 2016; 6:36338
Ahyayauch H, Villar AV, Alonso A, Goñi FM. Modulation of PI-specific phospholipase C by membrane curvature and molecular order. Biochemistry. 2005; 44:11592–11600
Broggi MAS, Maillat L, Clement CC, Bordry N, Corthésy P, Auger A, et al. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. J Exp Med. 2019; 216:1091–1107
García-Silva S, Benito-Martín A, Sánchez-Redondo S, Hernández-Barranco A, Ximénez-Embún P, Nogués L, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation. J Exp Med. 2019; 216:1061–1070
Bernhard H, Meyer zum Büschenfelde KH, Dippold WG. Ganglioside GD3 shedding by human malignant melanoma cells. Int J Cancer. 1989; 44:155–160
Portoukalian J, Zwingelstein G, Abdul-Malak N, Doré JF. Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem Biophys Res Commun. 1978; 85:916–920
Kannengiesser C, Spatz A, Michiels S, Eychène A, Dessen P, Lazar V, et al.; EORTC Melanoma group. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol. 2008; 1:425–430